Press Release

Rapid Drug Approvals for Blood Cancers are driving the Global Non-Hodgkin Lymphoma (NHL) Market

A recent research study published by MarkNtel Advisors states that the Global Non-Hodgkin Lymphoma (NHL) Market is set to register around 7.6% CAGR during 2022-27, mainly on account of the mounting instances of lymphomas and increasing investments in developing advanced therapeutics for the same. Besides, the excellent pipeline of targeted therapies, label expansion of existing lymphoma therapies, and increasing drug approvals for discovering more effective therapeutics are other crucial aspects augmenting the growth of the Global Non-Hodgkin Lymphoma Market.

Non-Hodgkin Lymphoma (NHL), which usually begins in lymph nodes, can turn lethal if not treated effectively. Globally, several clinical trials are being conducted by the leading biopharma companies toward new drug developments, particularly for the relapsed & refractory NHL cases, which have significantly helped improve the prognosis. Hence, these aspects also project lucrative growth opportunities for the market over the forecast years, further states the research report, "Global Non-Hodgkin Lymphoma (NHL) Market Analysis, 2022."

With Higher Efficacy & Fewer Side Effects than other Treatments, Monoclonal Antibodies Dominate the Global Market

Monoclonal antibodies (Immunotherapy) would continue their dominance in the Global Non-Hodgkin Lymphoma (NHL) Market during 2022-27, owing to their flexibility with other treatments, enhanced efficacy, & reduced adverse effects. As a result, they are considered ideal for targeting various subtypes of Non-Hodgkin Lymphoma, owing to which the major pharmaceutical firms worldwide, in order to expand their global presence, are increasing the indication of existing monoclonal antibodies for other cancer types.

Massive R&D Investments in Several Therapies across the US to Drive the North America Non-Hodgkin Lymphoma Market

North America, being home to the major biotechnology & pharmaceutical companies, holds the largest share in the Non-Hodgkin Lymphoma (NHL) Market globally. The US is the leading regional market owing to the rising incidence of B-cell lymphomas, well-established healthcare facilities, and massive investments in numerous ongoing research activities for finding advanced therapeutics for NHL treatment. These aspects, coupled with rapid approvals by FDA for novel drugs, would lead North America to continue its dominance in the market during 2022-27.

Competitive Landscape

The major companies in the Global Non-Hodgkin Lymphoma (NHL) Market include AstraZeneca PLC, AbbVie Inc., Baxter International Inc., Bayer AG, Bristol Myers Squibb, Eli Lilly and Company, GlaxoSmithKline PLC, F. Hoffmann-La Roche AG, Merck & Co., Inc., Novartis International AG, & Pfizer Inc.

Key Questions Answered in the Research Report

1. What are the current & future trends in the Global Non-Hodgkin Lymphoma (NHL) Market?
2. How has the industry been evolving in terms of geography & product adoption?
3. How has the competition been shaping across various regions, followed by their comparative factorial indexing?
4. What are the key growth drivers & challenges for the Global Non-Hodgkin Lymphoma (NHL) Market?
5. What are the customer orientation, purchase behavior, & expectations from the leading players in the Global Non-Hodgkin Lymphoma (NHL) Market?

Market Segmentation:

1. By Diagnosis (Biopsy (Excisional or Incisional, Needle, Bone Marrow Aspiration & Biopsy, Lumbar Puncture (Spinal Tap)), Lab Tests, Imaging (Chest X-Ray, CT Scan, MRI, PET Scan, Ultrasound), Blood Tests)
2. By Treatment (Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy (Monoclonal Antibodies, Antibody-drug Conjugates, Immunomodulatory Drugs, CAR T-cell therapy), Targeted Therapy, Radiation Therapy)
3. By End-User (Hospitals, Specialty Clinics, Others (Ambulatory Surgery Centers, etc.))
4. By Region (North America, South America, Europe, Middle East & Africa, Asia-Pacific)
5. By Country (The US, Canada, Mexico, Brazil, The UK, Germany, France, Italy, Spain, South Africa, GCC, China, Japan, India, Australia, South East Asia)